As per the analyst, the transformation consists of inventory and debt reduction, and divestitures, together with an agile organizational structure ... Eastman Chemical Company (NYSE:EMN) operates ...

Six years before the start of the COVID-19 pandemic, an Ebola outbreak in West Africa had people fearing the possibility of a ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

Researchers led by Prof. Dr. Hauke Hillen, head of the "Structure and Function of Molecular Machines" research group at the Department of Cellular Biochemistry at the University Medical Center ...

A natural antibacterial molecule shows clinical promise. Its unusual binding site is on an excellent target: ...

Now, the candidate has failed to match Eylea in a phase 3 trial, leaving the Australian biotech to consider its own future. The drug in question is sozinibercept, an inhibitor of vascular ...

An appeals court has upheld a District Court’s denial of a preliminary injunction for Amgen’s (AMGN) Eylea biosimilar, which UBS analyst Trung Huynh tells investors in “negative, but ...

The new molecular structure is, in the nomenclature of researchers, a “sandwich.” In this formation, a berkelium atom, serving as the filling, lays in between two 8-membered carbon rings — t ...

had infringed on U.S. Patent 11,084,865, claimed to cover a vial containing Eylea. As a result of the ruling, Amgen, which produces a biosimilar for Eylea, saw its shares increase by as much as 0.5%.

Strategic initiatives include launching biosimilars for Prolia, Symphony, and EYLEA, and exploring a potential listing on the Stockholm Exchange.

A mid-stage trial of 4D Molecular Therapeutics gene therapy for ... plus a reduced need for injections into the eye with current therapy Eylea. On the strength of the results, 4DMT is planning ...